These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 1680547

  • 21. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines.
    Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP, Shawver LK.
    Cancer Res; 1991 Sep 01; 51(17):4575-80. PubMed ID: 1678683
    [Abstract] [Full Text] [Related]

  • 22. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand.
    Lonardo F, Di Marco E, King CR, Pierce JH, Segatto O, Aaronson SA, Di Fiore PP.
    New Biol; 1990 Nov 01; 2(11):992-1003. PubMed ID: 1983208
    [Abstract] [Full Text] [Related]

  • 23. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.
    Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ.
    Oncogene; 1994 Jul 01; 9(7):1829-38. PubMed ID: 7911565
    [Abstract] [Full Text] [Related]

  • 24. Hemopexin joins transferrin as representative members of a distinct class of receptor-mediated endocytic transport systems.
    Smith A, Hunt RC.
    Eur J Cell Biol; 1990 Dec 01; 53(2):234-45. PubMed ID: 1964416
    [Abstract] [Full Text] [Related]

  • 25. Epitope mapping and functional studies with three monoclonal antibodies to the c-kit receptor tyrosine kinase, YB5.B8, 17F11, and SR-1.
    Ashman LK, Bühring HJ, Aylett GW, Broudy VC, Müller C.
    J Cell Physiol; 1994 Mar 01; 158(3):545-54. PubMed ID: 7510297
    [Abstract] [Full Text] [Related]

  • 26. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185.
    McKenzie SJ, Marks PJ, Lam T, Morgan J, Panicali DL, Trimpe KL, Carney WP.
    Oncogene; 1989 May 01; 4(5):543-8. PubMed ID: 2566965
    [Abstract] [Full Text] [Related]

  • 27. Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu.
    Mohanty K, Saha A, Pal S, Mallick P, Chatterjee SK, Foon KA, Bhattacharya-Chatterjee M.
    Breast Cancer Res Treat; 2007 Jul 01; 104(1):1-11. PubMed ID: 17004107
    [Abstract] [Full Text] [Related]

  • 28. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB, Hynes NE, Lane HA.
    Cancer Res; 2002 Jun 01; 62(11):3151-8. PubMed ID: 12036928
    [Abstract] [Full Text] [Related]

  • 29. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
    Ram TG, Ethier SP.
    Cell Growth Differ; 1996 May 01; 7(5):551-61. PubMed ID: 8732665
    [Abstract] [Full Text] [Related]

  • 30. Thrombomodulin lacking the cytoplasmic domain efficiently internalizes thrombin via nonclathrin-coated, pit-mediated endocytosis.
    Conway EM, Nowakowski B, Steiner-Mosonyi M.
    J Cell Physiol; 1994 Feb 01; 158(2):285-98. PubMed ID: 8106566
    [Abstract] [Full Text] [Related]

  • 31. Gene-specific inhibition of breast carcinoma in BALB-neuT mice by active immunization with rat Neu or human ErbB receptors.
    Masuelli L, Focaccetti C, Cereda V, Lista F, Vitolo D, Trono P, Gallo P, Amici A, Monaci P, Mattei M, Modesti M, Forni G, Kraus MH, Muraro R, Modesti A, Bei R.
    Int J Oncol; 2007 Feb 01; 30(2):381-92. PubMed ID: 17203220
    [Abstract] [Full Text] [Related]

  • 32. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
    Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ.
    Oncogene; 1998 Oct 29; 17(17):2235-49. PubMed ID: 9811454
    [Abstract] [Full Text] [Related]

  • 33. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
    Dean GS, Pusztai L, Xu FJ, O'Briant K, DeSombre K, Conaway M, Boyer CM, Mendelsohn J, Bast RC.
    Clin Cancer Res; 1998 Oct 29; 4(10):2545-50. PubMed ID: 9796989
    [Abstract] [Full Text] [Related]

  • 34. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
    Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, Benz CC, Papahadjopoulos D.
    Biochemistry; 1997 Jan 07; 36(1):66-75. PubMed ID: 8993319
    [Abstract] [Full Text] [Related]

  • 35. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
    Chang JY, Xia W, Shao R, Sorgi F, Hortobagyi GN, Huang L, Hung MC.
    Oncogene; 1997 Feb 06; 14(5):561-8. PubMed ID: 9053854
    [Abstract] [Full Text] [Related]

  • 36. Internalization and recycling of glycoprotein 280 in BN/MSV yolk sac epithelial cells: a model system of relevance to receptor-mediated endocytosis in the renal proximal tubule.
    Le Panse S, Verroust P, Christensen EI.
    Exp Nephrol; 1997 Feb 06; 5(5):375-83. PubMed ID: 9386973
    [Abstract] [Full Text] [Related]

  • 37. A combination of two immunotoxins exerts synergistic cytotoxic activity against human breast-cancer cell lines.
    Crews JR, Maier LA, Yu YH, Hester S, O'Briant K, Leslie DS, DeSombre K, George SL, Boyer CM, Argon Y.
    Int J Cancer; 1992 Jul 09; 51(5):772-9. PubMed ID: 1351885
    [Abstract] [Full Text] [Related]

  • 38. Demonstration by two-color flow cytometry that tyrosine kinase activity is required for down-modulation of the oncogenic neu receptor.
    Brown VI, Shah N, Smith R, Hellman M, Jarett L, Mikami Y, Cohen E, Qian X, Greene MI.
    DNA Cell Biol; 1994 Feb 09; 13(2):193-209. PubMed ID: 7910024
    [Abstract] [Full Text] [Related]

  • 39. Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185.
    Xu F, Lupu R, Rodriguez GC, Whitaker RS, Boente MP, Berchuck A, Yu Y, DeSombre KA, Boyer CM, Bast RC.
    Int J Cancer; 1993 Feb 01; 53(3):401-8. PubMed ID: 7679090
    [Abstract] [Full Text] [Related]

  • 40. The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin.
    Xu FJ, Boyer CM, Bae DS, Wu S, Greenwald M, O'Briant K, Yu YH, Mills GB, Bast RC.
    Int J Cancer; 1994 Oct 15; 59(2):242-7. PubMed ID: 7927925
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.